Everotas 10mg tablet - Everolimus | Myapplepharma
DESCRIPTION
Everotas 10mg belongs to the class of anti-cancer drugs Everotas 10mg contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down. Everotas 10mg tablets is not a curable medication, which helps to slow their spreading into the body.PRESCRIBED FOR
The drug Everotas 10mg is mainly used for the treatment of the following disease.• kidney carcinoma
• Breast carcinoma
• Brain carcinoma
Everotas 10mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas.
CLINICAL PHARMACOLOGY OF EVEROTAS
Everolimus is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis.Everotas also prohibits the expression of hypoxia-inducible factor, causing to a reduces in the expression of vascular endothelial growth factor. The result of everolimus prevention of mTOR is a reduction in cell multiplication, angiogenesis, and glucose uptake.DOSAGE
Everotas 10mg tablets should be given with or without food. Dosage regimen of Everotas; In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer: The prescribed dosage is 10mg should be taken as a single dose. In Brain or intracranial cancer: The prescribed dosage of Everotas as a single dose. is 4.5mg/m2 given orally In pediatric: The pediatric dosage of Everotas as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.SIDE EFFECTS
• Nephrotoxicity• Thrombocytopenia
• Hypersensitivity reactions
• Hyperlipemia
• Angioedema
• Lymphomas & other malignancy
• Male infertility
• Proteinuria
Comments
Post a Comment